Core Viewpoint - The company plans to increase its wholly-owned subsidiary, Sailong Bio, by converting its debt of 49,542,778.28 yuan into equity, which will raise Sailong Bio's registered capital from 55 million yuan to 104.5422778 million yuan, maintaining a 100% ownership stake [1] Group 1 - The capital increase will be executed through a debt-to-equity conversion, with no existing pledges, disputes, or judicial measures related to the debt [1] - The company aims to optimize resource allocation and enhance operational efficiency through this capital increase [1] Group 2 - The company intends to publicly transfer 100% of its equity in Sailong Bio, with the transfer price based on an assessment report from a valuation agency [1] - Upon successful completion of the equity transfer, the company will no longer hold any shares in Sailong Bio, and Sailong Bio will be excluded from the company's consolidated financial statements [1]
*ST赛隆(002898.SZ):拟对全资子公司赛隆生物以债转股方式进行增资并公开挂牌转让其股权